Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Marta Llorca, Cardenosa"'
Autor:
Christopher J. Lord, Alan Ashworth, Andrew N.J. Tutt, Jos Jonkers, Patrick W.B. Derksen, Colm J. Ryan, Rachael Natrajan, Spiros Linardopoulos, Mitch Dowsett, Lesley-Ann Martin, Elinor J. Sawyer, Fredrik Wallberg, Patrycja Gazinska, Irene Chong, Marta Llorca Cardenosa, Mark D. Gurden, Stephen J. Pettitt, Rahul Kumar, Aditi Gulati, James Campbell, Malini Menon, Dragomir B. Krastev, Asha Konde, Rumana Rafiq, Feifei Song, Jessica Frankum, Helen N. Pemberton, Rachel Brough, Marieke van de Ven, Rebecca Marlow, Ilirjana Bajrami
Lagging chromosomes in E-cadherin defective cell exposed to foretinib leading to failed cytokinesis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a46a503990fcd013cf24e9120ca5907e
https://doi.org/10.1158/2159-8290.22532777.v1
https://doi.org/10.1158/2159-8290.22532777.v1
Autor:
Christopher J. Lord, Alan Ashworth, Andrew N.J. Tutt, Jos Jonkers, Patrick W.B. Derksen, Colm J. Ryan, Rachael Natrajan, Spiros Linardopoulos, Mitch Dowsett, Lesley-Ann Martin, Elinor J. Sawyer, Fredrik Wallberg, Patrycja Gazinska, Irene Chong, Marta Llorca Cardenosa, Mark D. Gurden, Stephen J. Pettitt, Rahul Kumar, Aditi Gulati, James Campbell, Malini Menon, Dragomir B. Krastev, Asha Konde, Rumana Rafiq, Feifei Song, Jessica Frankum, Helen N. Pemberton, Rachel Brough, Marieke van de Ven, Rebecca Marlow, Ilirjana Bajrami
The cell adhesion glycoprotein E-cadherin (CDH1) is commonly inactivated in breast tumors. Precision medicine approaches that exploit this characteristic are not available. Using perturbation screens in breast tumor cells with CRISPR/Cas9-engineered
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06a759d0659ac60046b51092f46f3457
https://doi.org/10.1158/2159-8290.c.6546827
https://doi.org/10.1158/2159-8290.c.6546827
Autor:
Christopher J. Lord, Alan Ashworth, Andrew N.J. Tutt, Jos Jonkers, Patrick W.B. Derksen, Colm J. Ryan, Rachael Natrajan, Spiros Linardopoulos, Mitch Dowsett, Lesley-Ann Martin, Elinor J. Sawyer, Fredrik Wallberg, Patrycja Gazinska, Irene Chong, Marta Llorca Cardenosa, Mark D. Gurden, Stephen J. Pettitt, Rahul Kumar, Aditi Gulati, James Campbell, Malini Menon, Dragomir B. Krastev, Asha Konde, Rumana Rafiq, Feifei Song, Jessica Frankum, Helen N. Pemberton, Rachel Brough, Marieke van de Ven, Rebecca Marlow, Ilirjana Bajrami
Supplementary Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f28bf3060e5900c4f58b2c83cd17c64
https://doi.org/10.1158/2159-8290.22532786.v1
https://doi.org/10.1158/2159-8290.22532786.v1
Autor:
Christopher J. Lord, Alan Ashworth, Andrew N.J. Tutt, Jos Jonkers, Patrick W.B. Derksen, Colm J. Ryan, Rachael Natrajan, Spiros Linardopoulos, Mitch Dowsett, Lesley-Ann Martin, Elinor J. Sawyer, Fredrik Wallberg, Patrycja Gazinska, Irene Chong, Marta Llorca Cardenosa, Mark D. Gurden, Stephen J. Pettitt, Rahul Kumar, Aditi Gulati, James Campbell, Malini Menon, Dragomir B. Krastev, Asha Konde, Rumana Rafiq, Feifei Song, Jessica Frankum, Helen N. Pemberton, Rachel Brough, Marieke van de Ven, Rebecca Marlow, Ilirjana Bajrami
Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea0f27dec90521f076ecb04df7436b19
https://doi.org/10.1158/2159-8290.22532795
https://doi.org/10.1158/2159-8290.22532795
Autor:
Christopher J. Lord, Alan Ashworth, Andrew N.J. Tutt, Jos Jonkers, Patrick W.B. Derksen, Colm J. Ryan, Rachael Natrajan, Spiros Linardopoulos, Mitch Dowsett, Lesley-Ann Martin, Elinor J. Sawyer, Fredrik Wallberg, Patrycja Gazinska, Irene Chong, Marta Llorca Cardenosa, Mark D. Gurden, Stephen J. Pettitt, Rahul Kumar, Aditi Gulati, James Campbell, Malini Menon, Dragomir B. Krastev, Asha Konde, Rumana Rafiq, Feifei Song, Jessica Frankum, Helen N. Pemberton, Rachel Brough, Marieke van de Ven, Rebecca Marlow, Ilirjana Bajrami
Supplementary Figure legends and methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d07c82e10c0054f11b2153f2f4f13ad
https://doi.org/10.1158/2159-8290.22532792
https://doi.org/10.1158/2159-8290.22532792
Autor:
Isma Rana, David Watkins, Lauren I. Aronson, Naureen Starling, Sheela Rao, Ian Chau, Retchel Lazaro-Alcausi, Irene Chong, Ruwaida Begum, Hanna Bryant, Marta Llorca Cardenosa, Michael Davidson, Monica Terlizzo, Sanna Hulkki-Wilson, John Swansbury, Julie Howard-Reeves, David Cunningham, Christopher J. Lord, Gina Brown, Eftheleria Kalaitzaki, Andrew Wotherspoon, Kyriakos Kouvelakis, Rosalind J. Cutts
Publikováno v:
European Journal of Cancer. 122:12-21
The MYC proto-oncogene is among the most commonly dysregulated genes in human cancers. We report screening data from the iMYC trial, an ongoing phase II study assessing ibrutinib monotherapy in advanced pretreated MYC- and/or HER2-amplified oesophago
Autor:
Christopher J. Lord, Syed Haider, Ioannis Assiotis, Irene Chong, Ruwaida Begum, Naureen Starling, Nik Matthews, Asif Chaudry, Marta Llorca-Cardenosa, David Watkins, Monica Terlizzo, Andrew Wotherspoon, Ian Chau, Lauren I. Aronson, Alistair G. Rust, Ritika Chauhan, Sheela Rao, John Alexander, David Cunningham, Kerry Fenwick, Sacheen Kumar
Publikováno v:
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 10, Iss 215, p 215 (2021)
Journal of Clinical Medicine, Vol 10, Iss 215, p 215 (2021)
1. Background: The application of massively parallel sequencing has led to the identification of aberrant druggable pathways and somatic mutations within therapeutically relevant genes in gastro-oesophageal cancer. Given the widespread use of formali
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
Autor:
Jean-Charles Soria, Sophie Postel-Vinay, Mathieu Rouanne, Alan Ashworth, Rebecca Marlow, Roman M. Chabanon, Christopher J. Lord, Andrew Lamb, Ilirjana Bajrami, Andrew Tutt, Daphné Morel, Dragomir B. Krastev, Nicolas Dorvault, Asha Konde, Aurélien Marabelle, Clémence Hénon, Marta Llorca Cardenosa, Benjamin Besse, Stephen J. Pettitt, Marlène Garrido, Syed Haider, Julien Adam, Gareth Muirhead
Publikováno v:
The Journal of clinical investigation. 129(3)
The cyclic GMP-AMP synthase/stimulator of IFN genes (cGAS/STING) pathway detects cytosolic DNA to activate innate immune responses. Poly(ADP-ribose) polymerase inhibitors (PARPi) selectively target cancer cells with DNA repair deficiencies such as th
Autor:
Ilirjana, Bajrami, Rebecca, Marlow, Marieke, van de Ven, Rachel, Brough, Helen N, Pemberton, Jessica, Frankum, Feifei, Song, Rumana, Rafiq, Asha, Konde, Dragomir B, Krastev, Malini, Menon, James, Campbell, Aditi, Gulati, Rahul, Kumar, Stephen J, Pettitt, Mark D, Gurden, Marta Llorca, Cardenosa, Irene, Chong, Patrycja, Gazinska, Fredrik, Wallberg, Elinor J, Sawyer, Lesley-Ann, Martin, Mitch, Dowsett, Spiros, Linardopoulos, Rachael, Natrajan, Colm J, Ryan, Patrick W B, Derksen, Jos, Jonkers, Andrew N J, Tutt, Alan, Ashworth, Christopher J, Lord
Publikováno v:
Bajrami, I, Marlow, R, van de Ven, M, Brough, R, Pemberton, H N, Frankum, J, Song, F, Rafiq, R, Konde, A, Krastev, D B, Menon, M, Campbell, J, Gulati, A, Kumar, R, Pettitt, S J, Gurden, M D, Cardenosa, M L, Chong, I, Gazinska, P, Wallberg, F, Sawyer, E J, Martin, L-A, Dowsett, M, Linardopoulos, S, Natrajan, R, Ryan, C J, Derksen, P W B, Jonkers, J, Tutt, A N J, Ashworth, A & Lord, C J 2018, ' E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer ', Cancer discovery, vol. 8, no. 4, pp. 498-515 . https://doi.org/10.1158/2159-8290.CD-17-0603
Cancer Discovery, 8(4), 498. American Association for Cancer Research Inc.
Cancer discovery, vol 8, iss 4
Cancer Discovery, 8(4), 498. American Association for Cancer Research Inc.
Cancer discovery, vol 8, iss 4
The cell adhesion glycoprotein E-cadherin (CDH1) is commonly inactivated in breast tumors. Precision medicine approaches that exploit this characteristic are not available. Using perturbation screens in breast tumor cells with CRISPR/Cas9-engineered
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::24b9226c5040508d02ebf52140d0bf85
https://kclpure.kcl.ac.uk/ws/files/94235825/E_Cadherin_ROS1_Inhibitor_BAJRAMI_Accepted23January2018_GREEN_AAM.pdf
https://kclpure.kcl.ac.uk/ws/files/94235825/E_Cadherin_ROS1_Inhibitor_BAJRAMI_Accepted23January2018_GREEN_AAM.pdf
Autor:
Aditi Gulati, Rajesh Kumar, Mitch Dowsett, Ilirjana Bajrami, Elinor J. Sawyer, Rebecca Marlow, Stephen J. Pettitt, James Campbell, Lesley-Ann Martin, Asha Konde, Malini Menon, Marta Llorca Cardenosa, Helen N. Pemberton, Colm J. Ryan, Patrick W. B. Derksen, Alan Ashworth, Fredrik Wallberg, Spiros Linardopoulos, Marieke van de Ven, Andrew Tutt, Rachel Brough, Jos Jonkers, Patrycja Gazinska, Christopher J. Lord, Rumana Rafiq, Jessica Frankum, Irene Chong, Mark D. Gurden, Fei Fei Song
Publikováno v:
Cancer Research. 78:2986-2986
The E-cadherin (CDH1) tumour suppressor gene encodes a calcium-dependent cell-cell adhesion glycoprotein, which has roles in maintaining cell polarity, differentiation, cell migration and survival. E-cadherin dysfunction is a feature common to many e